Experienced in Ovarian Carcinosarcoma

Dr. Christine H. Holschneider

Gynecologic Oncology | Oncology
14445 Olive View Dr Rm 2b-163, Department Of Ob-gyn, 
Sylmar, CA 
Experienced in Ovarian Carcinosarcoma
14445 Olive View Dr Rm 2b-163, Department Of Ob-gyn, 
Sylmar, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christine Holschneider is a Gynecologic Oncologist and an Oncologist in Sylmar, California. Dr. Holschneider is rated as an Experienced provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Cervical Cancer, Ovarian Cancer, Cervical Dysplasia, Lymphadenectomy, and Hysterectomy.

Her clinical research consists of co-authoring 27 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Licenses
Obstetrics & Gynecology in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

14445 Olive View Dr Rm 2b-163, Department Of Ob-gyn, Sylmar, CA 91342

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2025
Intervention Type: Drug
Study Drugs: Tisotumab Vedotin, Bevacizumab, Pembrolizumab, Carboplatin
Study Phase: Phase 1/Phase 2
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 3
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)
Enrollment Status: Active_not_recruiting
Publish Date: May 03, 2024
Intervention Type: Other
Study Phase: Not Applicable
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 03, 2024
Intervention Type: Other, Procedure
Study Phase: Not Applicable
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Device, Drug
Study Drug: Paclitaxel
Study Phase: Phase 3
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Unknown
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
Enrollment Status: Unknown
Publish Date: January 25, 2022
Intervention Type: Biological, Drug, Other
Study Drugs: Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide Phosphate, Paclitaxel
Study Phase: Phase 2
View 8 Less Clinical Trials

27 Total Publications

Attitudes Toward Telehealth Visits Among Spanish- and English-Speaking Patients in a Safety-Net Gynecological Oncology Clinic.
Attitudes Toward Telehealth Visits Among Spanish- and English-Speaking Patients in a Safety-Net Gynecological Oncology Clinic.
Journal: Telemedicine journal and e-health : the official journal of the American Telemedicine Association
Published: March 25, 2025
Similar Doctors
Distinguished in Ovarian Carcinosarcoma
Dr. Robert E. Bristow
Gynecologic Oncology | Oncology | Rheumatology
Distinguished in Ovarian Carcinosarcoma
Dr. Robert E. Bristow
Gynecologic Oncology | Oncology | Rheumatology

Regents Of The University Of California

101 The City Dr S, 
Orange, CA 
 (48.9 miles away)
714-456-7002
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Bristow is a Gynecologic Oncologist and an Oncologist in Orange, California. Dr. Bristow is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. His top areas of expertise are Ovarian Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Oophorectomy, and Hysterectomy.

Distinguished in Ovarian Carcinosarcoma
Dr. Sanaz Memarzadeh
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Ovarian Carcinosarcoma
Dr. Sanaz Memarzadeh
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Regents Of The University Of California

100 Medical Plz, Suite 383, 
Los Angeles, CA 
 (18.0 miles away)
310-983-1023
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sanaz Memarzadeh is a Gynecologic Oncologist and an Oncologist in Los Angeles, California. Dr. Memarzadeh is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Vulvectomy, and Hernia Surgery.

Distinguished in Ovarian Carcinosarcoma
Dr. Thanh H. Dellinger
Gynecologic Oncology | Oncology
Distinguished in Ovarian Carcinosarcoma
Dr. Thanh H. Dellinger
Gynecologic Oncology | Oncology

City Of Hope Medical Foundation

209 Fair Oaks Ave, 
South Pasadena, CA 
 (21.9 miles away)
626-396-2900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thanh Dellinger is a Gynecologic Oncologist and an Oncologist in South Pasadena, California. Dr. Dellinger is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Hepato-Pancreato-Biliary Surgery.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Holschneider's expertise for a condition
ConditionClose
      View All 15 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile